Janney Montgomery Scott LLC Increases Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Janney Montgomery Scott LLC grew its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 30.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 66,487 shares of the company’s stock after buying an additional 15,332 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Cellebrite DI were worth $1,465,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in CLBT. Quarry LP bought a new position in Cellebrite DI in the third quarter valued at $27,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after purchasing an additional 1,017 shares in the last quarter. Advisors Asset Management Inc. increased its position in shares of Cellebrite DI by 130.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares during the last quarter. Pathway Financial Advisers LLC raised its holdings in shares of Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after buying an additional 4,118 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its position in Cellebrite DI by 28.6% in the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company’s stock worth $152,000 after buying an additional 2,000 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CLBT. Needham & Company LLC boosted their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Craig Hallum lifted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI currently has a consensus rating of “Buy” and an average price target of $21.57.

Cellebrite DI Stock Performance

CLBT stock opened at $24.67 on Tuesday. The firm has a 50 day moving average price of $21.77 and a 200-day moving average price of $18.46. Cellebrite DI Ltd. has a 52-week low of $8.91 and a 52-week high of $24.89. The firm has a market capitalization of $5.08 billion, a price-to-earnings ratio of -15.92, a PEG ratio of 3.55 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The business had revenue of $106.90 million during the quarter, compared to analysts’ expectations of $102.06 million. During the same quarter in the previous year, the business earned $0.09 earnings per share. The firm’s quarterly revenue was up 27.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Cellebrite DI Ltd. will post 0.32 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.